H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating on Argenx (ARGX) with a $617 price target after the company said it is advancing efgartigimod subcutaneous in all three subtypes of myositis based on positive Phase 2 results. The firm says efgartigimod could potentially be the first targeted treatment for myositis. Given cost and ease of use, it expects efgartigimod would be used ahead of cell therapy.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARGX:
- Argenx SE Boosts Myositis Treatment Development
- Argenx to continue development of efgartigimod subcutaneous
- Argenx and Zai Lab’s CIDP Drug Approved in China
- Nvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls
- Argenx upgraded to Outperform from Peer Perform at Wolfe Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
